Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (Concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217–1226.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145.
   PubMed Web of Science ®Google Scholar
• Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55–62.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart M, Gelber R, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London, England). 2017;389(10075):1195–1205.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–3752.
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66(1):111–128.
   PubMed Web of Science ®Google Scholar
• Molina-Montes E, Requena M, Sanchez-Cantalejo E, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol. 2015;136(1):158–171.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. Int J Cancer. 2020;146(2):352–362.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106.
   PubMed Web of Science ®Google Scholar
• Katuwal S, Jousilahti P, Pukkala E. Causes of death among women with breast cancer: a follow-up study of 50 481 women with breast cancer in Finland. Int J Cancer. 2021. doi:10.1002/ijc.33607
   PubMed Web of Science ®Google Scholar
• Rusner C, Wolf K, Bandemer-Greulich U, et al. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. Breast Cancer Res. 2014;16(5):452.
   PubMed Web of Science ®Google Scholar
• Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer. 2006;94(11):1745–1750.
   PubMed Web of Science ®Google Scholar
• Qian X, Jia H, Zhang Y, Ma B, Qin G, Wu Z. Risk factors and prediction of second primary cancer in primary female non-metastatic breast cancer survivors. Aging. 2020;12(19):19628–19640.
   PubMedGoogle Scholar
• Schonfeld SJ, Curtis RE, Anderson WF, Berrington de González A. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. Cancer Causes Control. 2012;23(10):1721–1728.
   PubMed Web of Science ®Google Scholar
• Li D, Weng S, Zhong C, et al. Risk of second primary cancers among long-term survivors of breast cancer. Front Oncol. 2019;9:1426.
   PubMed Web of Science ®Google Scholar
• Wei JL, Jiang YZ, Shao ZM. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol. 2019;24(8):934–940.
   PubMed Web of Science ®Google Scholar
• Jeyakumar A, Chua T, Lam A, Gopalan V. The melanoma and breast cancer association: an overview of their ‘second primary cancers’ and the epidemiological, genetic and biological correlations. Crit Rev Oncol Hematol. 2020;152:102989.
   PubMed Web of Science ®Google Scholar
• Wei J, Jiang Y, Shao Z. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol. 2019;24(8):934–940.
   PubMed Web of Science ®Google Scholar
• Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast. 2017;35:122–129.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Visser O, Louwman M, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26(8):1239–1246.
   PubMed Web of Science ®Google Scholar
• Marcheselli R, Marcheselli L, Cortesi L, et al. Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer. 2015;18(4):378–385.
   PubMed Web of Science ®Google Scholar
• Andersson M, Jensen M, Engholm G, Henrik Storm H. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncologica (Stockholm, Sweden). 2008;47(4):755–764.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Pappas L, Matsen C, Agarwal J. Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy. Cancer Med. 2020;9(21):8043–8052.
   PubMed Web of Science ®Google Scholar
• Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer. 1932;16(1):1358–1414.
   Google Scholar
• Curtis RE, Freedman DM, Ries LAG, et al. Methods. In: Curtis RE, Freedman DM, Ron E, editors. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute. NIH Publ. No. 05-5302; 2006:9–14.
   Google Scholar
• Hammond M, Hayes D, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–922.
   PubMed Web of Science ®Google Scholar
• Wolff A, Hammond M, Allison K, et al. Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122.
   PubMed Web of Science ®Google Scholar
• Liddell F. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health. 1984;38(1):85–88.
   PubMed Web of Science ®Google Scholar
• Yasui Y, Liu Y, Neglia J, et al. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003;158(11):1108–1113.
   PubMed Web of Science ®Google Scholar
• Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2 Pt 1):559–565.
   PubMed Web of Science ®Google Scholar
• Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388–1395.
   PubMed Web of Science ®Google Scholar
• Hotta K, Yanai H, Ohashi K, et al. Pilot evaluation of a HER2 testing in non-small-cell lung cancer. J Clin Pathol. 2020;73(6):353–357.
   PubMed Web of Science ®Google Scholar
• Kuyama S, Hotta K, Tabata M, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thor Oncol. 2008;3(5):477–482.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–278.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003;9:3645–3652.
   PubMed Web of Science ®Google Scholar
• Abrahao-Machado L, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619–4625.
   PubMed Web of Science ®Google Scholar
• Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N Y). 1989;244(4905):707–712.
   PubMed Web of Science ®Google Scholar
• Nam A, Kim J, Cha Y, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7(36):58007–58021.
   PubMedGoogle Scholar
• Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108–1119.
   PubMed Web of Science ®Google Scholar
• Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21(9):70.
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.
   PubMed Web of Science ®Google Scholar
• Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Swain S, Baselga J, Kim S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• Huang KL, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355e314–370e314.
   Web of Science ®Google Scholar
• Armakolas A, Stathopoulos G, Nezos A, Theos A, Stathaki M, Koutsilieris M. Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients. Oncol Rep. 2012;28(6):2255–2263.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Armakolas A. Differences in gene expression between individuals with multiple primary and single primary malignancies. Int J Mol Med. 2009;24(5):613–622.
   PubMed Web of Science ®Google Scholar
• Fountzilas E, Konstantopoulou I, Vagena A, et al. Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections. Clin Breast Cancer. 2020;20(2):152–159.
   PubMed Web of Science ®Google Scholar